The congress offers relevant content and experts in:
- Immune profiling
- Bioprocessing and manufacturing
- Cancer and immunotherapy vaccines
- Clinical trials
- Emerging and re-emerging diseases
- Influenza and respiratory vaccines
- Vaccine partnerships
- Veterinary vaccines
- Vaccine safety
- Vaccine logistics
Title: Control Potential Viral Contaminants in Vaccines and Biologics with Effective Testing
The release of vaccines and biopharmaceuticals into clinical trials or for application as licensed products requires regulatory authority approval of data from appropriate tests to ensure the products are free from potential adventitious agent contamination.
The historical incidents during the1970s, when patients with haemophilia and blood related conditions were infected with HIV and other blood-borne viruses after being given treatment using proteins isolated from human plasma, are well documented and have resulted in the establishment of clearly defined testing strategies and methods to ensure known and potential unknown contaminating adventitious agents can be detected in vaccine and biopharmaceutical products.
This webinar will outline current testing strategies for a range of vaccines and biological substrates and focus on the types of validated assay method required to ensure detection of potential adventitious agents. Differences in approved assay methods such as cultivation methods and marker methods will be presented. SGS's facility in Glasgow is a GMP approved testing facility offering a range of validated methods to test a wide range of cell banks and viral vaccine seeds.
Meet the team to find out more about our clinical trials services and biosafety solutions.
For further information, please contact:
t: +32 15 27 32 45